Trial Profile

Clinical and Genetic Determinants of Disease Progression and Response to Sacubitril/Valsartan vs Lifestyle (Physical Activity and Dietary Nitrate) in Patients With Hypertrophic Cardiomyopathy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Aug 2023 Primary endpoint (Peak Oxygen Consumption (ml/kg/min)) has not been met, according to results presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology.
28 Aug 2023 Results (n=115) of patients with symptomatic non-obstructive HCM (NYHA class I to III) who were randomly assigned (2:1) to receive sacubitril/valsartan (target dose 97/103mg) or usual care for 16 weeks presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology.
23 Nov 2022 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com